Stroke is still the second leading cause of death in the world， seriously threatening human health. The most common related diseases that cause stroke include atherosclerosis， hypertension， atrial fibrillation， diabetes， etc. At present， the main treatment methods for acute ischemic stroke include thrombolytic therapy and mechanical thrombectomy therapy. However， due to the limitation of the treatment time window and the damage caused by ischemia-reperfusion， it is urgent to find new treatment methods from the potential molecular mechanism of stroke， so as to provide effective treatments for stroke and reduce the harm caused by stroke to the population. Long non-coding RNA（ LncRNA） is a kind of RNA that is located in the nucleus or cytoplasm and has no coding ability. The growth arrest-specific 5（ GAS5） is a member of the LncRNA family. Studies have shown that LncRNA GAS5（ Long non-coding RNA GAS5） can participate in the cell cycle， proliferation and apoptosis processes directly or indirectly， leading to the occurrence and development of stroke and various diseases. This article reviews its role in the occurrence and development of stroke and related diseases， aiming to reveal the role of LncRNA GAS5 as a potential biomarker and therapeutic target in stroke.